Zealand Pharma A/S at Goldman Sachs Healthcare C-Suite Unscripted Conference Transcript
Hi, everyone. Thanks for joining us for the next session. I'm pleased that we have Adam Steensberg, who's CEO of Zealand Pharma with us today. Adam, thanks for joining us and making the trip over in person. Maybe just kind of to kick it off, if you wanted to kind of make some high-level introductory comments about Zealand, about the pipeline, about therapeutic focus for some of the people that may be less familiar with the company.
/- -
Absolutely. And thank you for the invitation. Great to be here. So Zealand Pharma is a Danes-based biotech company focused on peptide drug discovery and development. We have a very strong pipeline within obesity, both assets in phase 1 through Phase 3, and together with our partner Boehringer, one of them.
And then we have opportunities in rare diseases and chronic inflammation, so basically leveraging our peptide drug discovery and development skills, which we have been refining, I would say, over 25
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |